Flu activity is low, but experts worry about a new strain and vaccination rates

The U.S. flu season has started slowly but CDC data shows a new H3N2 subclade K—different from this year’s vaccine strain—is driving most early infections; a preliminary UK analysis indicates current vaccines may still offer partial protection. Policymakers and clinicians warn the season could become severe as in 2023–24 (over 18,000 flu deaths and the highest hospitalization rate since the 2009 H1N1 pandemic), and vaccination signals are mixed: IQVIA reports over two million fewer pharmacy flu shots through October while CDC survey data shows children’s uptake at ~34% and adults at ~37%; COVID vaccine up‑to‑date rates have also fallen (children ~6%, adults ~14%). Compounding uncertainty, a recent government shutdown disrupted CDC surveillance and shifts under Health Secretary Robert F. Kennedy Jr. have reduced federal vaccine promotion, creating risks for preparedness and potential strain on hospitals and related healthcare sectors if cases accelerate through the winter.

Analysis

U.S. flu activity is currently low with only one state (Louisiana) reporting moderate activity, but CDC data shows most early infections are a new H3N2 subclade K that differs from the strain used in this season’s vaccine; a preliminary U.K. analysis indicates current shots may offer partial protection. Reported cases are concentrated in children, and as typical seasonal dynamics suggest, illnesses could accelerate through December–February as travel and gatherings increase. Vaccination signals are mixed: IQVIA reports over two million fewer pharmacy flu shots through October year‑over‑year, while CDC survey data shows child uptake at ~34% (unchanged) and adult uptake at ~37% (up a few points); COVID vaccine up‑to‑date rates have fallen to ~6% for children and ~14% for adults. Surveillance and public messaging are impaired by a recent government shutdown that halted CDC data collection and by reduced federal vaccine promotion under the new Health Secretary, which together increase uncertainty about real‑time trends and raise the risk of another severe season that could stress hospitals, insurers and supply chains.

Key Decisions for Investors

• Monitor incoming U.K. and CDC vaccine effectiveness analyses and weekly hospitalization metrics; if data confirm reduced protection and rising admissions, consider increasing exposure to defensive healthcare sectors (hospitals, acute care suppliers) and vaccine production/distribution plays
• Track IQVIA pharmacy vaccination fills and CDC uptake surveys closely; a sustained shortfall from last year (e.g., continuation of >2M fewer pharmacy doses) should trigger risk reduction in cyclical consumer and elective healthcare exposures
• Watch for restoration of CDC surveillance and federal public‑health messaging stability; ongoing data gaps and anti‑vaccine rhetoric warrant preserving liquidity and avoiding leverage into seasonal demand trades until reporting normalizes
• Prepare tactical optionality for a severe winter (buy protection or hedge correlated equities) while maintaining neutral baseline positioning given current low activity but elevated tail‑risk from the new H3N2 subclade